Departments of Neuropathology, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Schwabachanlage 6, 91054, Erlangen, Germany.
ENDOC Center for Endocrine Tumors, Hamburg & University of Duisburg-Essen, Essen, Germany.
Acta Neuropathol Commun. 2015 Aug 19;3:50. doi: 10.1186/s40478-015-0229-8.
The term atypical pituitary adenoma (APA) was revised in the 2004 World Health Organization (WHO) classification of pituitary tumors. However, two of the four parameters required for the diagnosis of APAs were formulated rather vaguely (i.e., "extensive" nuclear staining for p53; "elevated" mitotic index). Based on a case-control study using a representative cohort of typical pituitary adenomas and APAs selected from the German Pituitary Tumor Registry, we aimed to obtain reliable cut-off values for both p53 and the mitotic index. In addition, we analyzed the impact of all four individual parameters (invasiveness, Ki67-index, p53, mitotic index) on the selectivity for differentiating both adenoma subtypes.
Of the 308 patients included in the study, 98 were diagnosed as APAs (incidence 2.9 %) and 10 patients suffered from a pituitary carcinoma (incidence 0.2 %). As a control group, we selected 200 group matched patients with typical pituitary adenomas (TPAs). Cut-off values were attained using ROC analysis.
We determined significant threshold values for p53 (≥2 %; AUC: 0.94) and the mitotic index (≥2 mitosis within 10 high power fields; AUC: 0.89). The most reliable individual marker for differentiating TPAs and APAs was a Ki-67-labeling index ≥ 4 % (AUC: 0.98). Using logistic regression analysis (LRA) we were able to show that all four criteria (Ki-67 (p < 0.001); OR 5.2// p53 (p < 0.001); OR 3.1// mitotic index (p < 0.001); OR 2.1// invasiveness (p < 0.001); OR 8.2)) were significant for the group of APAs. Furthermore, we describe the presence of nucleoli as a new favorable parameter for TPAs (p = 0.008; OR: 0.4; CI95 %: 0.18; 0.77).
Here we present a proposed rectification of the current WHO classification of pituitary tumors describing an additional marker for TPA and specific threshold values for p53 and the mitotic index. This will greatly help in the reliable diagnosis of APAs and facilitate further studies to ascertain the prognostic relevance of this categorization.
在 2004 年世界卫生组织(WHO)垂体肿瘤分类中,对“非典型垂体腺瘤(APA)”这一术语进行了修订。然而,APA 诊断所需的四个参数中的两个(即 p53 的“广泛”核染色;有丝分裂指数“升高”)的表述相当模糊。基于一项使用德国垂体肿瘤登记处代表性典型垂体腺瘤和 APA 病例对照研究,我们旨在为 p53 和有丝分裂指数获得可靠的截断值。此外,我们分析了所有四个单独参数(侵袭性、Ki67 指数、p53、有丝分裂指数)对区分这两种腺瘤亚型的选择性的影响。
在纳入研究的 308 例患者中,98 例诊断为 APA(发生率 2.9%),10 例患有垂体癌(发生率 0.2%)。作为对照组,我们选择了 200 例与典型垂体腺瘤(TPA)相匹配的患者。使用 ROC 分析获得截断值。
我们确定了 p53(≥2%;AUC:0.94)和有丝分裂指数(≥2 个有丝分裂/10 个高倍视野;AUC:0.89)的显著阈值值。区分 TPA 和 APA 的最可靠的单个标志物是 Ki-67 标记指数≥4%(AUC:0.98)。使用逻辑回归分析(LRA),我们能够表明,所有四个标准(Ki-67(p<0.001);OR 5.2//p53(p<0.001);OR 3.1//有丝分裂指数(p<0.001);OR 2.1//侵袭性(p<0.001);OR 8.2))对 APA 组具有统计学意义。此外,我们描述了核仁的存在作为 TPA 的一个新的有利参数(p=0.008;OR:0.4;95%CI:0.18;0.77)。
在这里,我们提出了对当前 WHO 垂体肿瘤分类的修正,描述了 TPA 的另一个标志物和 p53 和有丝分裂指数的特定截断值。这将极大地帮助 APA 的可靠诊断,并促进进一步的研究,以确定这种分类的预后相关性。